SAB Biotherapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

SABS$3.07-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

	For The Three Months Ended June 30,		For The Six Months Ended June 30,
	2026	2025	2026	2025
Operating expenses
Research and development	16,172	6,997	29,570	14,654
General and administrative	7,205	2,735	13,805	5,850
Total operating expenses	23,377	9,732	43,375	20,504
Loss from operations	(23,377)	(9,732)	(43,375)	(20,504)
Other income (expense)
Changes in fair value of warrant liabilities	(1,111)	(627)	(1,593)	4,409
Interest expense	(62)	(64)	(125)	(134)
Interest income	1,709	14	2,756	76
Other income, net	350	295	977	842
Total other income (expense)	886	(382)	2,015	5,193
Net loss	$(22,491)	$(10,114)	$(41,360)	$(15,311)
Other comprehensive income (loss):
Unrealized loss, change in fair value of available-for-sale securities	$(717)	$—	$(1,217)	$(1)
Reclassification adjustment for gain on sale of available-for-sale securities included in net income	—	—	(47)	—
Foreign currency translation gain	10	95	147	120
Total comprehensive loss	$(23,198)	$(10,019)	$(42,477)	$(15,192)
Loss per common share attributable to the Company’s shareholders
Basic and diluted loss per common share	$(0.28)	$(1.09)	$(0.62)	$(1.65)
Weighted-average common shares outstanding – basic and diluted	79,753,100	9,294,469	66,768,309	9,293,018

See accompanying notes to the condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.